Faye Feller Biography and Net Worth

Executive Vice President, Chief Medical Officer of Geron

Previously, she served as our Vice President of Clinical Development since she joined Geron in April 2019. In this role, Dr. Feller played a strategic role in designing and driving execution of Geron’s Phase 3 clinical trials, served as the primary medical point of contact between Geron and our clinical investigators and led the preparation of data for assessment by the data monitoring committees.

Prior to joining Geron, Dr. Feller was Senior Director at Janssen Research and Development, LLC (Janssen), a global pharmaceutical company, and both a Compound Lead and Study Responsible Physician for multiple clinical trials of early and late-stage development assets at Janssen from February 2015 to March 2019. Prior to Janssen, Dr. Feller was an instructor in the leukemia department of Memorial Sloan Kettering Cancer Center in New York from July 2013 to February 2015. She received a B.A. from New York University and an M.D. from Mount Sinai School of Medicine. She completed her residency in internal medicine at Mount Sinai Hospital and her fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.

How do I contact Faye Feller?: The corporate mailing address for Dr. Feller and other Geron executives is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. Geron can also be reached via phone at (650) 473-7700 and via email at [email protected]. Learn More on Faye Feller's contact information.
Has Faye Feller been buying or selling shares of Geron?: Faye Feller has not been actively trading shares of Geron during the last ninety days. Most recently, Faye Feller sold 287,900 shares of the business's stock in a transaction on Monday, June 10th. The shares were sold at an average price of $4.63, for a transaction totalling $1,332,977.00. Learn More on Faye Feller's trading history.
Who are Geron's active insiders?: Geron's insider roster includes Faye Feller (Executive Vice President, Chief Medical Officer), Andrew Grethlein (xecutive Vice President, Chief Operating Officer), V. Lawlis (Director), Susan Molineaux (Director), Elizabeth O'Farrell (Director), Scott Samuels (Executive Vice President, Chief Legal Officer and Secretary), John Scarlett (CEO), and Robert Spiegel (Director). Learn More on Geron's active insiders.

Faye Feller Insider Trading History at Geron

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/10/2024	Sell	287,900	$4.63	$1,332,977.00

Faye Feller Buying and Selling Activity at Geron

Geron Company Overview

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Today's Range

Now: $1.67

$1.66

$1.79

50 Day Range

MA: $1.62

$1.40

$1.95

2 Week Range

Now: $1.67

$1.04

$2.01

Volume

16,567,749 shs

Average Volume

19,557,790 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield